Download Library

 
 
 
Download Library
Document Type
Interim Report for the First Nine Months of 2017
pdf
589.5 KB
A Phase IIa Study of Tisotumab Vedotin (HuMax-TF-ADC) in Patients With Relapsed, Recurrent and/or Metastatic Cervical Cancer: Updated Safety and Efficacy - ESGO E-poster - November 2017 (Concin)
PDF
453.8 KB
Daratumumab, Lenalidomide and Dexamethasone vs Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy & Safety Analysis of POLLUX - ASH abstract - November 2017 (Dimopoulos)
URL
N/A
Daratumumab, Bortezomib and Dexamethasone vs Bortezomib and Dexamethasone for Relapsed / Refractory Multiple Myeloma Patients: An Update of Overall Survival in CASTOR - ASH abstract - November 2017 (Lentzsch)
URL
N/A
Interim Safety Analysis of a Phase II Randomized Study of Daratumumab, Lenalidomide, Bortezomib and Dexamethasone vs Lenalidomide, Bortezomib and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Eligible for HDT and ASCT- ASH abstract -November 2017 (Voorhees)
URL
N/A
Safety and Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed and Refractory Multiple Myeloma: Final Results from GEN501 and SIRIUS - ASH abstract - November 2017 (Usmani)
URL
N/A
Daratumumab Monotherapy for Patients with Intermediate or High-risk Smoldering Multiple Myeloma: CENTAURUS - ASH abstract - November 2017 (Hofmeister)
URL
N/A
Daratumumab, Lenalidomide and Dexamethasone vs Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Based on Prior Treatment History, Renal Function, and Cytogenetic Risk: Subgroup Analyses of POLLUX - ASH abstract - November 2017 (Moreau)
URL
N/A
Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma (MMY1001) - ASH abstract - November 2017 (Lonial)
URL
N/A
Results of an Interim Safety Analysis of a Phase II Study of Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone in Previously Untreated and Relapsed Patients with Multiple Myeloma - ASH abstract - November 2017 (Yimer)
URL
N/A
Daratumumab in Combination with Lenalidomide Plus Dexamethasone Results in Persistent Natural Killer Cells with a Distinct Phenotype and Expansion of Effector Memory T-cells in POLLUX - ASH abstract - November 2017 (van de Donk)
URL
N/A
Cost-effectiveness of Daratumumab Plus Lenalidomide Plus Dexamethasone vs Lenalidomide Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: an Analysis of the POLLUX Trial - ASH abstract - November 2017 (Maiese)
URL
N/A
Daratumumab in Combination with Lenalidomide and Dexamethaone in Patients with Relapsed or Relapsed / Refractory Multiple Myeloma (GEN503): Final Results - ASH abstract - November 2017 (Plesner)
URL
N/A
Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma in Patients with greater than or equal to 2 Prior Lines of Therapy: Updated Analysis of MMY1001 - ASH abstract - November 2017 (Facon)
URL
N/A
Daratumumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma (MMY1001) - ASH abstract - November 2017 (Chari)
URL
N/A
Cost-effectiveness of Daratumumab Plus Bortezomib and Dexamethasone Versus Bortezomib Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: an Analysis of the CASTOR Trial - ASH abstract - November 2017 (Maiese)
URL
N/A
Subcutaneous Delivery of Daraumumab in Patients with Relapsed or Refractory Multiple Myeloma: PAVO - ASH abstract - November 2017 (Chari)
URL
N/A
Daratumumab, Bortezomib and Dexamethasone vs Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Analysis of CASTOR - ASH abstract - November 2017 (Spencer)
URL
N/A
Efficacy and Safety of Ofatumumab and Bendamustine Followed by Ofatumumab Maintenance in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma After Prior Rituximab - ASH abstract - November 2017 (Kolibaba)
URL
N/A
Investor Presentation, September 2017
PDF
2.6 MB
A Phase I/II Safety Study of Tisotumab Vedotin (HuMax-TF-ADC) in Patients With Solid Tumours - ESMO Poster - September 2017 (Chenard-Poirier)
PDF
958.9 KB
A Phase IIA Study of Tisotumab Vedotin (HuMax-TF-ADC) in Patients with Relapsed, Recurrent and / or Metastatic Cervical Cancer - ESMO presentation - September 2017 (Vergote)
PDF
626.4 KB
A phase IIa study of tisotumab vedotin (HuMax-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer - ESMO abstract - August 2017 (Vergote)
URL
N/A
A phase I/II safety study of tisotumab vedotin (HuMax-TF-ADC) in patients with solid tumors - ESMO abstract - August 2017 (Chenard-Poirier)
URL
N/A
Q2 2017 Results Podcast
MP3
24.9 MB

Page: First Previous
1
2
3
4
5
6
...
19
Next Last

 
 
 

Please be advised that additional documents and media, such as fact sheets and conference call webcasts, are available only in English and can be accessed by clicking on the English tab.

 

Download Library
Document Type
Lovpligtig redegørelse for virksomhedsledelse 2011
PDF
129.3 KB
Lovpligtig redegørelse for samfundsansvar 2011
PDF
31.7 KB
Årsrapport 2011
PDF
1.8 MB
Lovpligtig redegørelse for virksomhedsledelse 2010
PDF
131.1 KB
Genmab offentliggør resultat for de første ni måneder af 2011 og opdaterede resultatforventninger til 2011
PDF
287.4 KB
Delårsrapport pr. 30. juni 2011
PDF
286.0 KB
Delårsrapport for 1. kvartal 2011
PDF
278.3 KB
Årsregnskabsmeddelelse 2010
PDF
686.1 KB
Delårsrapport pr. 30. september 2010
PDF
248.7 KB
Delårsrapport pr. 30. juni 2010
PDF
328.8 KB
Delårsrapport for 1. kvartal 2010
PDF
293.7 KB
Årsrapport 2010
PDF
2.5 MB
Årsregnskabsmeddelelse 2009
PDF
688.2 KB
Årsrapport 2009
PDF
2.5 MB
Delårsrapport pr. 30. september 2009
PDF
319.1 KB
Delårsrapport pr. 30. juni 2009
PDF
161.1 KB
Delårsrapport for 1. kvartal 2009
PDF
192.8 KB
Årsregnskabsmeddelelse 2008
PDF
518.9 KB
Årsrapport 2008
PDF
3.7 MB
Kvartalsrapport for perioden 1. januar til 30. september 2008
PDF
181.5 KB
Halvårsrapport pr. 30. juni 2008
PDF
212.3 KB
Kvartalsrapport for 1. kvartal 2008
PDF
263.1 KB
Årsrapport 2007
PDF
2.2 MB
Kvartalsrapport for perioden 1. januar til 30. september 2007
PDF
284.5 KB
Halvårsrapport pr. 30. juni 2007
PDF
274.6 KB
Page: First Previous
1
2
3
4
Next Last